


AURA3 primary endpoint: PFS by investigator assessment



	No. at risk					
Osimertinib	279	240	162	88	50	13
Platinum-pemetrexed	140	93	44	17	7	1

Analysis of PFS by BICR was consistent with the investigator-based analysis: **HR 0.28** (95% CI 0.20, 0.38), p<0.001; median PFS 11.0 vs 4.2 months.

Population: intent-to-treat

Progression-free survival defined as time from randomisation until date of objective disease progression or death; calculated using the Kaplan-Meier approach. Progression included deaths in the absence of RECIST progression.

Tick marks indicate censored data; CI, confidence interval

Papadimitrakopoulou V, et al. AURA3. To be presented at 17th WCLC, hosted by IASLC. December 2016.